

Ref. _MDA26-090_____

ASSIGNMENT

This Patent Assignment (“Assignment”) is made and entered into by and between COURTNEY DINARDO (the “Assignor(s)”) and BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, having a place of business at 210 West 7th Street, Austin, Texas 78701 (the “Assignee”).

WHEREAS, Assignor(s) has agreed to assign and transfer to Assignee, and Assignee has agreed to acquire and accept from Assignor(s), Assignor(s)’s rights in the following patent application(s) (the “Assigned Patents”):

U.S. PCT Patent Application No. PCT/US2024/036827 filed July 3, 2024, entitled “TREATMENT OF ACUTE MYELOID LEUKEMIA WITH OLUTASIDENIB, VENETOCLAX AND A HYPOMETHY-LATING AGENT”

U.S Non-Provisional Patent Application No. 19/499.807 filed January 6, 2026 entitled “TREATMENT OF ACUTE MYELOID LEUKEMIA WITH OLUTASIDENIB, VENETOCLAX AND A HYPOMETHY-LATING AGENT”

NOW, THEREFORE, in consideration of the premises, mutual covenants, and provisions herein contained, the receipt and sufficiency of which is hereby acknowledged, and intending to be legally bound hereby, the parties hereto agree to execute this Assignment, as follows:

1.0 Assignment. The Assignor(s) has assigned and/or by these presents does hereby assign, transfer, and convey unto Assignee, the Assignor(s)’s whole and entire right, title, and interest for the United States and all other countries throughout the world (i) in and to the inventions claimed or disclosed in the Assigned Patents, including all patents granting from the Assigned Patents or any conversion to international patent application (i.e., PCT application), non-provisional, continuation, continuation-in-part, division, renewal, substitute, reexamination, or reissue thereof, including any patents in the United States and in all other countries throughout the world obtained based upon a claim of priority to any said Assigned Patents as provided for by United States law, the Patent Cooperation Treaty, the European Patent Convention, the Paris Convention, or other applicable law, as well as the right to claim priority to any said Assigned Patents as provided for by United States law, the Patent Cooperation Treaty, the European Patent Convention, the Paris Convention, or other applicable law, and (ii) in and to all rights to sue for and collect damages resulting from past, present, and future infringement of said patents and patent applications in (i).

2.0 Enjoyment. The above-described patents and patent applications subject to Paragraph 1.0 above shall be held and enjoyed by Assignee, for Assignee’s use and benefit, and for Assignee’s legal representatives and assigns, to the full end of the term or terms for which same may be granted, as fully and entirely as the same would have been held by Assignor(s) had this assignment and transfer not been made.

3.0 Authorize and Request. Assignor(s) authorizes and requests the issuing authority to issue any and all United States and foreign patents granted on such patents and patent applications described above to the Assignee.

4.0 Warrant and Covenant. Assignor(s) warrants and covenants that no assignment, grant, mortgage, license, or other agreement affecting the rights and property herein conveyed has been or will be made to others by the Assignor(s), and that the full right to convey the same as herein expressed is possessed by the Assignor(s).

5.0 Assistance. The parties to this Assignment shall use commercially reasonable efforts to take, or cause to be taken, all actions, and to do, or cause to be done, all things necessary or advisable to consummate the transactions contemplated by this Assignment. Without limiting the foregoing, each of Assignor(s) and Assignee shall cooperate with the other without any further consideration to execute and deliver, or use commercially reasonable efforts to cause to be executed and delivered, all documents as may reasonably be necessary to secure the vesting in Assignee of all rights assigned to Assignee by this Assignment, including without limitation any documents required to record this Assignment with local patent offices, and all rightful oaths, declarations, and other papers.

We grant Assignee the power to insert on this Assignment any information that may be necessary or desirable in order to comply with all applicable legal requirements, including the rules of the United States Patent and Trademark Office, for submitting and recording this document.

6.0 Binding. The Assignment is binding on the heirs, assigns, representatives, and successors of the Assignor(s) and extends to the successors, assigns, and nominees of the Assignee.

7.0 Effectiveness. The assignment of said inventions is or was effective as of the earlier of (1) the date of execution of the Assignor(s) indicated below or (2) the filing date of the first filed of the patent applications of the Assigned Patents.

Signature page(s) to follow

Executed for the purposes stated herein, on the date as noted below.

ASSIGNORS:

Courtney DiNardo

Signature

3/25/2026 | 9:11 AM CDT

Courtney DiNardo

Date

Acknowledged and Accepted by ASSIGNEE:

BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

RP

Signature

Ryan Pierce

Printed/Typed Name

Associate General Counsel

Title

March 30, 2026

Date

PATENT RIGHTS ASSIGNMENT

This Patent Rights Assignment (this “Assignment”) is made effective by and between Board of Regents of The University of Texas System, an agency of the State of Texas having a place of business located at 210 West 7th Street, Austin, Texas 78701 (“Assignor”), and Rigel Pharmaceuticals, Inc., a corporation of Delaware having a usual place of business at 611 Gateway Blvd., Suite 900, South San Francisco, CA 94080 (“Assignee”).

WHEREAS, Assignor owns the entire right, title and interest of U.S. PCT Patent Application No. PCT/US2024/036827, filed on July 3, 2024, and entitled, **TREATMENT OF ACUTE MYELOID LEUKEMIA WITH OLUTASIDENIB, VENETOCLAX AND A HYPOMETHY-LATING AGENT** AND U.S. Patent Application No. 19/499,807, filed on January 6, 2026, and entitled, **TREATMENT OF ACUTE MYELOID LEUKEMIA WITH OLUTASIDENIB, VENETOCLAX AND A HYPOMETHY-LATING AGENT** (the “Patent Rights”) and the invention(s) described and/or claimed in the Patent Rights (the “Inventions”); and

WHEREAS, Assignor now wishes to assign the Inventions and Patent Rights to Assignee, and Assignee desires to acquire the Inventions and Patent Rights from Assignor.

NOW, THEREFORE, in consideration of the mutual covenants and promises contained herein, and for other good and valuable consideration the receipt and sufficiency of which is hereby acknowledged, Assignor and Assignee hereby agree as follows:

1. Assignor does hereby sell, assign, convey and transfer unto Assignee and its successors, assigns, and legal representatives, Assignor’s entire right, title and interest, which Assignee accepts, in and throughout the world in and to the Inventions, together with Assignor’s entire right, title and interest, which Assignee accepts, in and to the Patent Rights and such other patents as may issue thereon or claim priority under United States law or international or foreign convention, including but not limited to non-provisionals, continuations, divisionals, continuations-in-part, reissues, reexaminations, extensions, and substitutions of patents and patent applications within the Patent Rights or such other patents, and any right, title and interest Assignor may have in applications to which the Patent Rights claim priority and the right to claim priority to the Patent Rights; the Inventions and the Patent Rights to be held and enjoyed by Assignee for its own use and behalf and for its successors, assigns and legal representatives, to the full end of the term for which said patents may be granted as fully and entirely as the same would have been held by Assignor had this assignment and sale not been made; and Assignor hereby conveys all of its rights arising under or pursuant to any and all United States laws and foreign and international agreements, treaties or laws relating to the protection of industrial property by filing any such applications for patent, including but not limited to any cause(s) of action and damages accruing prior to this assignment, including all rights to exclude others from practicing the claimed invention(s) and all rights to seek any and all remedies in law or equity, including damages and injunctive relief, for past, present, and future infringement. Assignor hereby acknowledges that this assignment, being of Assignor’s entire right, title and interest in and to the Inventions and the Patent Rights carries with it the right in Assignee to apply for and obtain from competent authorities in all countries of the world any and all patents by attorneys

and agents of Assignee's selection and the right to procure the grant of all patents to Assignee in its own name as assignee of Assignor's entire right, title and interest therein.

2. Assignor does hereby authorize the Director of the United States Patent & Trademark Office, and the empowered officials of all other governments whose duty it is to record patents, applications and title thereto, to record the Patent Rights and title thereto as the property of Assignee, its successors, assigns, or legal representatives in accordance with the terms of this instrument.

3. Assignor does hereby further authorize and request the Director of the United States Patent and Trademark Office and the empowered officials of all other governments to issue such Patent Rights or patents as shall be granted upon the Patent Rights, or applications based thereon, to Assignee, its successors, assigns, or legal representatives.

4. Assignee and Assignor also agree that multiple copies of this Assignment may be executed, each of which shall be deemed an original, and each of which shall be valid and binding upon Assignee and Assignor.

BY SIGANTURES BELOW, Assignor and Assignee have caused this Assignment to be executed by their duly authorized representatives as of the date first written above.

Assignor Name: **BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM**

Signature: 

Printed Name: Ryan Pierce

Title: Associate General Counsel

Date: March 30, 2026

Assignee Name: **RIGEL PHARMACEUTICALS, INC.**

Signature: *Mike Ouimette*

Printed Name: Mike Ouimette

Corporate Title: Associate General Counsel

Date: 03/31/2026



UNITED STATES PATENT AND TRADEMARK OFFICE

UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND
DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE

MAY 10, 2024

PTAS

PAUL KINDER
201 REDWOOD SHORES PARKWAY
SUITE 200
REDWOOD CITY, CA 94065

508537766

UNITED STATES PATENT AND TRADEMARK OFFICE NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT RECORDATION BRANCH OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE ASSIGNMENT RECORDATION BRANCH AT 571-272-3350. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, MAIL STOP: ASSIGNMENT RECORDATION BRANCH, P.O. BOX 1450, ALEXANDRIA, VA 22313.

RECORDATION DATE: 05/08/2024

REEL/FRAME: 067353/0210
NUMBER OF PAGES: 4

BRIEF: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

DOCKET NUMBER: RIGL-162PRV

ASSIGNOR:

CHAO, MWE MWE

DOC DATE: 04/18/2024

ASSIGNEE:

RIGEL PHARMACEUTICALS, INC.
611 GATEWAY BOULEVARD
SOUTH SAN FRANCISCO, CALIFORNIA
94080

APPLICATION NUMBER: 63525639

FILING DATE: 07/07/2023

PATENT NUMBER:

ISSUE DATE:

TITLE: TREATMENT OF HEMATOLOGIC MALIGNANCIES OR PRE-MALIGNANCIES

ASSIGNMENT RECORDATION BRANCH
PUBLIC RECORDS DIVISION

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

Assignment ID: PATI219670

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	Mwe Mwe Chao	04/18/2024
RECEIVING PARTY DATA		
Company Name:	Rigel Pharmaceuticals, Inc.	
Street Address:	611 Gateway Boulevard	
City:	South San Francisco	
State/Country:	CALIFORNIA	
Postal Code:	94080	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	63525639
CORRESPONDENCE DATA		
Fax Number:	6503273231	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	6503273400	
Email:	kinder@bffllp.com	
Correspondent Name:	Paul Kinder	
Address Line 1:	201 Redwood Shores Parkway	
Address Line 2:	Suite 200	
Address Line 4:	Redwood City, CALIFORNIA 94065	
ATTORNEY DOCKET NUMBER:	RIGL-162PRV	
NAME OF SUBMITTER:	Paul Kinder	
SIGNATURE:	Paul Kinder	
DATE SIGNED:	05/08/2024	
Total Attachments: 3		
source=RIGL-162PRV_Assignment-EXE#page1.tif		
source=RIGL-162PRV_Assignment-EXE#page2.tif		
source=RIGL-162PRV_Assignment-EXE#page3.tif		

ASSIGNMENT OF APPLICATION

Atty Docket No. RIGL-162PRV

THIS ASSIGNMENT, by **Mwe Mwe Chao**, residing in South San Francisco, California 94080 (hereinafter referred to as the assignors), respectively, witnesseth:

WHEREAS, the said assignors have invented certain new and useful improvements in:

“Treatment of Hematologic Malignancies or Pre-Malignancies”

☒ for which an application was filed on July 7, 2023 as U.S. Application Serial No. 63/525,639.

WHEREAS, **Rigel Pharmaceuticals, Inc.** a corporation duly organized under and pursuant to the laws of Delaware, and having its principal place of business at 611 Gateway Boulevard, South San Francisco, California, 94080 (hereinafter referred to as the assignee) is desirous of acquiring said assignors' right, title and interest in and to said invention and said application, and in and to any Letters Patent or Patents, United States or foreign, to be obtained therefor and thereon:

NOW THEREFORE, for good and sufficient considerations, the receipt of which is hereby acknowledged, said assignors have sold, assigned, transferred and set over, and by these presents do sell, assign, transfer and set over, unto the assignee, its successors, legal representatives and assigns, all of said assignors' right, title and interest in and to, as well as the right to claim priority of, the above-mentioned invention, application, and any and all Letters Patent or Patents in the United States of America and all foreign countries which may be granted therefor and thereon, and in and to any and all divisions, continuations, and continuations-in-part of said application, or reissues or extensions of said Letters Patent or Patents, and all rights under the International Convention for the Protection of Industrial Property, the same to be held and enjoyed by said assignee, for its own use and behalf and the use and behalf of its successors, legal representatives and assigns, to the full end of the term or terms for which Letters Patent or Patents may be granted, as fully and entirely as the same would have been held and enjoyed by the assignors, had this sale and assignment not been made.

AND for the same consideration, said assignors hereby covenant and agree to and with said assignee, its successors, legal representatives and assigns, that, at the time of execution and delivery of these presents, no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment and that said assignors have good and full right and lawful authority to sell and convey the same in the manner herein set forth.

AND for the same consideration, said assignors hereby covenant and agree to and with said assignee, its successors, legal representatives and assigns, that said assignors will, whenever counsel of said assignee, or the counsel of its successors, legal representatives and assigns, shall advise that any proceeding in connection with said invention, or said application, or any proceeding in connection with Letters Patent for said invention in any country, including interference proceedings, is lawful and desirable, or that any division, continuation or continuation-in-part of any application or any reissue or extension of any Letters Patent, to be obtained thereon, is lawful and desirable, sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done for the procurement, maintenance, enforcement and defense of Letters Patent for said invention, without charge to said assignee, its successors, legal representatives and assigns, but at the cost and expense of said assignee, its successors, legal representatives and assigns.

AND said assignors hereby request the Commissioner of Patents to issue said Letters Patent of the United States to said assignee as the assignee of said invention and the Letters Patent to be issued thereon for the use and behalf of said assignee, its successors, legal representatives and assigns.

Date 18 Apr 24

Signature of Inventor


Mwe Mwe Chao

ASSIGNMENT OF APPLICATION

Atty Docket No. RIGL-162PRV

Hereby accepted on behalf of the assignee

Signature of authorized representative

April 18, 2024

Date

Jennifer Zari

Name (print)

Director, Legal

Rigel Pharmaceuticals, Inc.

Title and Company

CALIFORNIA ACKNOWLEDGMENT

CIVIL CODE § 1189

A notary public or other officer completing this certificate verifies only the identity of the individual who signed the document to which this certificate is attached, and not the truthfulness, accuracy, or validity of that document.


State of California

County of San Mateo

On April 18, 2024 before me, Paulina Elizabeth Balajadia, Public Notary
Date Here Insert Name and Title of the Officer

personally appeared Jennifer S. Zazi
Name(s) of Signer(s)

who proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.



I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct.

WITNESS my hand and official seal.

Signature

Signature of Notary Public

Place Notary Seal and/or Stamp Above

OPTIONAL

Completing this information can deter alteration of the document or fraudulent reattachment of this form to an unintended document.

Description of Attached Document

Title or Type of Document: _____

Document Date: _____ Number of Pages: _____

Signer(s) Other Than Named Above: _____

Capacity(ies) Claimed by Signer(s)

Signer's Name: _____

☐ Corporate Officer – Title(s): _____

☐ Partner – ☐ Limited ☐ General

☐ Individual ☐ Attorney in Fact

☐ Trustee ☐ Guardian or Conservator

☐ Other: _____

Signer is Representing: _____

Signer's Name: _____

☐ Corporate Officer – Title(s): _____

☐ Partner – ☐ Limited ☐ General

☐ Individual ☐ Attorney in Fact

☐ Trustee ☐ Guardian or Conservator

☐ Other: _____

Signer is Representing: _____

ASSIGNMENT OF APPLICATION

Atty Docket No. RIGL-162PRV

THIS ASSIGNMENT, by **Mwe Mwe Chao**, residing in South San Francisco, California 94080 (hereinafter referred to as the assignors), respectively, witnesseth:

WHEREAS, the said assignors have invented certain new and useful improvements in:

“Treatment of Hematologic Malignancies or Pre-Malignancies”

☒ for which an application was filed on July 7, 2023 as U.S. Application Serial No. 63/525,639.

WHEREAS, **Rigel Pharmaceuticals, Inc.** a corporation duly organized under and pursuant to the laws of Delaware, and having its principal place of business at 611 Gateway Boulevard, South San Francisco, California, 94080 (hereinafter referred to as the assignee) is desirous of acquiring said assignors' right, title and interest in and to said invention and said application, and in and to any Letters Patent or Patents, United States or foreign, to be obtained therefor and thereon:

NOW THEREFORE, for good and sufficient considerations, the receipt of which is hereby acknowledged, said assignors have sold, assigned, transferred and set over, and by these presents do sell, assign, transfer and set over, unto the assignee, its successors, legal representatives and assigns, all of said assignors' right, title and interest in and to, as well as the right to claim priority of, the above-mentioned invention, application, and any and all Letters Patent or Patents in the United States of America and all foreign countries which may be granted therefor and thereon, and in and to any and all divisions, continuations, and continuations-in-part of said application, or reissues or extensions of said Letters Patent or Patents, and all rights under the International Convention for the Protection of Industrial Property, the same to be held and enjoyed by said assignee, for its own use and behalf and the use and behalf of its successors, legal representatives and assigns, to the full end of the term or terms for which Letters Patent or Patents may be granted, as fully and entirely as the same would have been held and enjoyed by the assignors, had this sale and assignment not been made.

AND for the same consideration, said assignors hereby covenant and agree to and with said assignee, its successors, legal representatives and assigns, that, at the time of execution and delivery of these presents, no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment and that said assignors have good and full right and lawful authority to sell and convey the same in the manner herein set forth.

AND for the same consideration, said assignors hereby covenant and agree to and with said assignee, its successors, legal representatives and assigns, that said assignors will, whenever counsel of said assignee, or the counsel of its successors, legal representatives and assigns, shall advise that any proceeding in connection with said invention, or said application, or any proceeding in connection with Letters Patent for said invention in any country, including interference proceedings, is lawful and desirable, or that any division, continuation or continuation-in-part of any application or any reissue or extension of any Letters Patent, to be obtained thereon, is lawful and desirable, sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done for the procurement, maintenance, enforcement and defense of Letters Patent for said invention, without charge to said assignee, its successors, legal representatives and assigns, but at the cost and expense of said assignee, its successors, legal representatives and assigns.

AND said assignors hereby request the Commissioner of Patents to issue said Letters Patent of the United States to said assignee as the assignee of said invention and the Letters Patent to be issued thereon for the use and behalf of said assignee, its successors, legal representatives and assigns.

Date 18 Apr 24

Signature of Inventor


Mwe Mwe Chao

ASSIGNMENT OF APPLICATION

Atty Docket No. RIGL-162PRV

Hereby accepted on behalf of the assignee

Signature of authorized representative

April 18, 2024

Date

Jennifer Zari

Name (print)

Director, Legal

Rigel Pharmaceuticals, Inc.

Title and Company

CALIFORNIA ACKNOWLEDGMENT

CIVIL CODE § 1189

A notary public or other officer completing this certificate verifies only the identity of the individual who signed the document to which this certificate is attached, and not the truthfulness, accuracy, or validity of that document.


State of California

County of San Mateo

On April 18, 2024 before me, Paulina Elizabeth Balajadia, Public Notary
Date Here Insert Name and Title of the Officer

personally appeared Jennifer S. Zazi
Name(s) of Signer(s)

who proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.



I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct.

WITNESS my hand and official seal.

Signature

Signature of Notary Public

Place Notary Seal and/or Stamp Above

OPTIONAL

Completing this information can deter alteration of the document or fraudulent reattachment of this form to an unintended document.

Description of Attached Document

Title or Type of Document: _____

Document Date: _____ Number of Pages: _____

Signer(s) Other Than Named Above: _____

Capacity(ies) Claimed by Signer(s)

Signer's Name: _____

☐ Corporate Officer – Title(s): _____

☐ Partner – ☐ Limited ☐ General

☐ Individual ☐ Attorney in Fact

☐ Trustee ☐ Guardian or Conservator

☐ Other: _____

Signer is Representing: _____

Signer's Name: _____

☐ Corporate Officer – Title(s): _____

☐ Partner – ☐ Limited ☐ General

☐ Individual ☐ Attorney in Fact

☐ Trustee ☐ Guardian or Conservator

☐ Other: _____

Signer is Representing: _____